Patients whose cancers were hormone receptor (HR) negative – that is, their tumor cells did not have proteins that bind to ...

Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) ...

SAN ANTONIO -- Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed ...

Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

So far, “the only established risk factors for prostate cancer are advancing age, African ancestry, and a family history of ...

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a ...